| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, ... The Lancet Oncology 24 (3), 273-285, 2023 | 46 | 2023 |
| The Cannabis Effects Expectancy Questionnaire–Medical (CEEQ-M): Preliminary psychometric properties and longitudinal validation within a clinical trial. JH Weiss, B Tervo-Clemmens, KW Potter, AE Evins, JM Gilman Psychological assessment 35 (8), 659, 2023 | 2 | 2023 |
| The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries E Jain, JGT Zanudo, M McGillicuddy, DL Abravanel, BS Thomas, D Kim, ... medRxiv, 2023.06. 07.23291117, 2023 | 2 | 2023 |
| Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab M Lipsyc-Sharf, E Jain, LC Collins, SM Rosenberg, KJ Ruddy, RM Tamimi, ... JCO Precision Oncology 7, e2300076, 2023 | 1 | 2023 |
| Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers N Priedigkeit, A Lebrón-Torres, J Liao, JB Alberge, S Morganti, J Weiss, ... Cancer Research 84 (9_Supplement), GS03-09-GS03-09, 2024 | | 2024 |
| Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer H Parsons, C Messer, K Santos, J Weiss, D Merrell, B Danysh, M Hughes, ... | | 2024 |
